SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Temozolomide Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
             Innishannon
             County Cork - Ireland
   Telephone : 353 214329300
   Telefax : 908-735-1496
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Acute toxicity, Category 2 : H300: Fatal if swallowed.
   Eye irritation, Category 2 : H319: Causes serious eye irritation.
   Germ cell mutagenicity, Category 2 : H341: Suspected of causing genetic defects.
   Carcinogenicity, Category 2 : H351: Suspected of causing cancer.
   Reproductive toxicity, Category 1B : H360FD: May damage fertility. May damage the unborn child.
   Specific target organ toxicity - repeated exposure, Category 1 : H372: Causes damage to organs through prolonged or repeated exposure.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms :
   Signal word : Danger
   Hazard statements : H300 Fatal if swallowed.
                     H319 Causes serious eye irritation.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Formulation

Version 4.4  Revision Date: 09/13/2019  SDS Number: 25445-00015  Date of last issue: 24.04.2019
Date of first issue: 24.10.2014

H341 Suspected of causing genetic defects.
H351 Suspected of causing cancer.
H360FD May damage fertility. May damage the unborn child.
H372 Causes damage to organs through prolonged or repeated exposure.

Precautionary statements:

Prevention:
P201 Obtain special instructions before use.
P260 Do not breathe dust.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.

Hazardous components which must be listed on the label:
Temozolomide

2.3 Other hazards
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temozolomide</td>
<td>85622-93-1</td>
<td></td>
<td></td>
<td></td>
<td>Acute Tox. 2; H300 Mut. 2; H341 Carc. 2; H351 Repr. 1B; H360FD STOT RE 1; H372</td>
<td>&gt;= 50 - &lt; 70</td>
</tr>
<tr>
<td>(+)-Tartaric acid</td>
<td>87-69-4 201-766-0</td>
<td></td>
<td></td>
<td></td>
<td>Eye Dam. 1; H318</td>
<td>&gt;= 1 - &lt; 3</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures
General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.
Call a physician or poison control centre immediately.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Fatal if swallowed.
Causes serious eye irritation.
Suspected of causing genetic defects.
Suspected of causing cancer.
May damage fertility. May damage the unborn child.
Causes damage to organs through prolonged or repeated exposure.
Contact with dust can cause mechanical irritation or drying of the skin.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing : None known.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Formulation

Version 4.4
Revision Date: 09/13/2019
SDS Number: 25445-00015
Date of last issue: 24.04.2019
Date of first issue: 24.10.2014

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products: Carbon oxides, Nitrogen oxides (NOx), Metal oxides

5.3 Advice for firefighters
Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions
Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding
SAFETY DATA SHEET 
according to Regulation (EC) No. 1907/2006

Temozolomide Formulation

Version 4.4 Revision Date: 09/13/2019 SDS Number: 25445-00015 Date of last issue: 24.04.2019 Date of first issue: 24.10.2014

certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents Organic peroxides Flammable liquids Flammable solids Pyrophoric liquids Pyrophoric solids Self-heating substances and mixtures Substances and mixtures, which in contact with water, emit flammable gases Explosives Gases

7.3 Specific end use(s)
Temozolomide Formulation

Version 4.4 Revision Date: 09/13/2019 SDS Number: 25445-00015 Date of last issue: 24.04.2019 Date of first issue: 24.10.2014

Specific use(s) : No data available

No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temozolomide</td>
<td>85622-93-1</td>
<td>TWA</td>
<td>0.1 ug/m3 (OEB 5)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>1 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(+)-Tartaric acid</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>5.2 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>2.9 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>1.3 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>1.5 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>8.1 mg/kg bw/day</td>
</tr>
<tr>
<td>Stearic acid</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>17.63 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>10 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>4.348 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>5 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>2.5 mg/kg bw/day</td>
</tr>
</tbody>
</table>

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(+)-Tartaric acid</td>
<td>Fresh water</td>
<td>0.3125 mg/l</td>
</tr>
<tr>
<td></td>
<td>Freshwater - intermittent</td>
<td>0.514 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.3125 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>10 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>1.141 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>1.141 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>0.0449 mg/kg dry weight (d.w.)</td>
</tr>
</tbody>
</table>
8.2 Exposure controls

Engineering measures
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Eye protection
Wear the following personal protective equipment:
Safety goggles
Equipment should conform to I.S. EN 166

Hand protection

Material
Chemical-resistant gloves

Remarks
Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Skin and body protection
Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Respiratory protection
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type
Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance
Powder

Colour
Off-white

Odour
No data available

Odour Threshold
No data available

pH
No data available

Melting point/freezing point
No data available

Initial boiling point and boiling range
No data available

Flash point
No data available

Evaporation rate
No data available
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 1 g/cm³

Solubility(ies)
   Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
   Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Molecular weight : No data available

Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
   Not classified as a reactivity hazard.

10.2 Chemical stability
   Stable under normal conditions.

10.3 Possibility of hazardous reactions
   Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Formulation

Version 4.4 Revision Date: 09/13/2019 SDS Number: 25445-00015 Date of last issue: 24.04.2019
Date of first issue: 24.10.2014

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure: Inhalation, Skin contact, Ingestion, Eye contact

Acute toxicity
Fatal if swallowed.

Product:
Acute oral toxicity: Acute toxicity estimate: 33.93 mg/kg
Method: Calculation method

Components:

Temozolomide:
Acute oral toxicity: LD50 (Dog): 19 mg/kg
LD50 (Rat): 315 mg/kg
LD50 (Mouse): 205 mg/kg

(+)-Tartaric acid:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423

Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation
Not classified based on available information.

Components:

(+)-Tartaric acid:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation
Serious eye damage/eye irritation
Causes serious eye irritation.

**Components:**

(+)-Tartaric acid:
Species: Bovine cornea
Method: OECD Test Guideline 437
Result: Irreversible effects on the eye

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

**Components:**

**Temozolomide:**
Test Type: Maximisation Test
Exposure routes: Dermal
Species: Guinea pig
Result: negative

(+)-Tartaric acid:
Test Type: Local lymph node assay (LLNA)
Exposure routes: Skin contact
Species: Mouse
Method: OECD Test Guideline 429
Result: negative

Germ cell mutagenicity
Suspected of causing genetic defects.

**Components:**

**Temozolomide:**
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: positive
Test Type: Chromosome aberration test in vitro
Test system: Human lymphocytes
Result: positive

Germ cell mutagenicity- Assessment: Positive results from in vitro mammalian mutagenicity assays, chemical structure activity relationship to known germ cell mutagens
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
</table>

(+)‐Tartaric acid:

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Bacterial reverse mutation assay (AMES)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
<tr>
<td></td>
<td>Remarks: Based on data from similar materials</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Chromosome aberration test in vitro</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
<tr>
<td></td>
<td>Remarks: Based on data from similar materials</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result: positive</td>
</tr>
</tbody>
</table>

Genotoxicity in vivo:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Mutagenicity (in vivo mammalian bone‐marrow cyogenetic test, chromosomal analysis)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Rat</td>
</tr>
</tbody>
</table>
| Application Route | Ingestion

Carcinogenicity

Suspected of causing cancer.

Components:

Temozolomide:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>: 4 mg/kg body weight</td>
<td></td>
</tr>
<tr>
<td>Result</td>
<td>positive</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Mammary gland</td>
</tr>
<tr>
<td>Carcinogenicity - Assessment</td>
<td>Limited evidence of carcinogenicity in animal studies</td>
</tr>
</tbody>
</table>

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

Temozolomide:

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Fertility/early embryonic development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Rat, male</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Fertility</td>
<td>LOAEL: 8.5 mg/kg body weight</td>
</tr>
<tr>
<td>Result</td>
<td>positive</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on foetal development</th>
<th>Test Type: Embryo‐foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Rat</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Embryo‐foetal toxicity</td>
<td>LOAEL: 13 mg/kg body weight</td>
</tr>
<tr>
<td>Result</td>
<td>positive, Malformations were observed.</td>
</tr>
</tbody>
</table>

Reproductive toxicity - Assessment:

Clear evidence of adverse effects on sexual function and fertil-
(Tartaric acid):

Effects on foetal development:

- Test Type: Embryo-foetal development
- Species: Rat
- Application Route: Ingestion
- Result: negative

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

**Components:**

**Temozolomide:**

<table>
<thead>
<tr>
<th>Exposure routes</th>
<th>Ingestion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Organs</td>
<td>Bone marrow, thymus gland, Lymph nodes, spleen</td>
</tr>
<tr>
<td>Assessment</td>
<td>Causes damage to organs through prolonged or repeated exposure</td>
</tr>
</tbody>
</table>

**Repeated dose toxicity**

**Components:**

**Temozolomide:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat, female</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>4 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>21 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Lymph nodes, thymus gland, Bone marrow, Reproductive organs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat, male</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>8.5 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>34 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Lymph nodes, thymus gland, Bone marrow, male reproductive organs, Gastrointestinal tract</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>2.5 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>6.3 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Bone marrow, spleen, male reproductive organs, Gastrointestinal tract, thymus gland</td>
</tr>
</tbody>
</table>
13 / 17

SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Formulation

Version 4.4
Revision Date: 09/13/2019
SDS Number: 25445-00015
Date of last issue: 24.04.2019
Date of first issue: 24.10.2014

(+) TARTARIC ACID:
Species: Rat
NOAEL: > 100 mg/kg
Application Route: Ingestion
Exposure time: 2 yr

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Temozolomide:
Ingestion:
Symptoms: Blood disorders, Nausea, Vomiting, Diarrhoea, anorexia, Fatigue, hair loss

SECTION 12: Ecological information

12.1 Toxicity

Components:

Temozolomide:
Toxicity to fish:
LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants:
EC50 (Pseudokirchneriella subcapitata (green algae)): > 90 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 40 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms:
EC50: > 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish:
LC50 (Danio rerio (zebra fish)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other:
EC50 (Daphnia magna (Water flea)): 93.313 mg/l
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Temozolomide Formulation

Version 4.4  Revision Date: 09/13/2019  SDS Number: 25445-00015  Date of last issue: 24.04.2019

aquatic invertebrates

Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 51.404 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3.125 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 : > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

12.2 Persistence and degradability

Components:

Temozolomide:
Biodegradability: Result: rapidly degradable
Biodegradation: 83 %
Exposure time: 35 d

Stability in water: Degradation half life (DT50): < 1 d

(+) -Tartaric acid:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 85 %
Exposure time: 28 d
Method: OECD Test Guideline 306

12.3 Bioaccumulative potential

Components:

Temozolomide:
Partition coefficient: n-octanol/water: log Pow: 1.35

(+) -Tartaric acid:
Partition coefficient: n-octanol/water: log Pow: -1.91

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available
SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EC) No 850/2004 on persistent organic pollutants: Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information
Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H300: Fatal if swallowed.
H318: Causes serious eye damage.
H341: Suspected of causing genetic defects.
H351: Suspected of causing cancer.
H360FD: May damage fertility. May damage the unborn child.
H372: Causes damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations
Acute Tox.: Acute toxicity
Carc.: Carcinogenicity
Eye Dam.: Serious eye damage
Muta.: Germ cell mutagenicity
Repr.: Reproductive toxicity
STOT RE: Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response;
Further information

Classification of the mixture:

- Acute Tox. 2: H300 - Calculation method
- Eye Irrit. 2: H319 - Calculation method
- Muta. 2: H341 - Calculation method
- Carc. 2: H351 - Calculation method
- Repr. 1B: H360FD - Calculation method
- STOT RE 1: H372 - Calculation method

Classification procedure:

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN